nitazoxanide has been researched along with Disease Exacerbation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barreto-Alves, JA; do Nascimento-Júnior, EM; Fakhouri, R; Ferreira, LC; Martins-Filho, PR | 1 |
| Byrne, P; Harrington, P; O Murchu, E; O'Neill, M; Ryan, M; Spillane, S | 1 |
| Abdollahi, M; Ganjali, Z; Javan, MR; Khalseh, R; Khani, M; Ramroodi, N; Ravan, H; Sanadgol, E; Sanadgol, N | 1 |
| Frosch, M; Müller, A; Stich, A; Tappe, D | 1 |
2 review(s) available for nitazoxanide and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
Topics: Anti-Inflammatory Agents; Antiparasitic Agents; Antiviral Agents; COVID-19 Drug Treatment; Disease Progression; Humans; Lactate Dehydrogenases; Nitro Compounds; Randomized Controlled Trials as Topic; SARS-CoV-2; Thiazoles | 2022 |
Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review.
Topics: Ambulatory Care; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; Disease Progression; Humans; Interferons; Ivermectin; Nitro Compounds; Polyethylene Glycols; Thiazoles | 2022 |
2 other study(ies) available for nitazoxanide and Disease Exacerbation
| Article | Year |
|---|---|
Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis.
Topics: Animals; Blood-Brain Barrier; CD11b Antigen; Cell Movement; Cerebral Cortex; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Inflammation Mediators; Integrin alpha4beta1; Leukocyte Common Antigens; Leukocytes; Male; Mice; Monocytes; Multiple Sclerosis; Nitro Compounds; Oligopeptides; Permeability; RNA, Messenger; Thiazoles | 2015 |
Limitations of amphotericin B and nitazoxanide in the treatment of alveolar echinococcosis.
Topics: Amphotericin B; Anthelmintics; Disease Progression; Drug Therapy, Combination; Echinococcosis, Hepatic; Follow-Up Studies; Humans; Male; Middle Aged; Nitro Compounds; Thiazoles; Treatment Failure | 2009 |